Therapeutic Improvement of a Stroma-targeted CRAd by Incorporating Motives Responsive to the Melanoma Microenvironment

Overview

Journal J Invest Dermatol

Publisher Elsevier

Specialty Dermatology

Date 2013 Apr 23

PMID 23604101

Citations 12

Authors

Diego L Viale

Eduardo G Cafferata

David Gould

Cecilia Rotondaro

Yuti Chernajovsky

David T Curiel

Osvaldo L Podhajcer

M Veronica Lopez

Affiliations

Soon will be listed here.

Abstract

We have previously designed a conditionally replicative oncolytic adenovirus (CRAd) named Ad-F512 that can target both the stromal and the malignant melanoma cell compartments. The replication capacity of this CRAd is driven by a 0.5-Kb SPARC promoter fragment (named F512). To improve CRAd's efficacy, we cloned into F512 motives responsive to hypoxia (hypoxia-responsive element (HRE)) and inflammation (nuclear factor kappa B) to obtain a chimeric promoter named κBF512HRE. Using luciferase as a reporter gene, we observed 10-15-fold increased activity under hypoxia and 10-80-fold induction upon tumor necrosis factor-α addition. We next constructed a CRAd (Ad-κBF512HRE) where E1A activity was under κBF512HRE regulation. Treatment of nude mice harboring established tumors made of a mix of SB2 melanoma cells and WI-38 fibroblasts with Ad-κBF512HRE led to the complete elimination of tumors in 100% of mice (8/8). Moreover, Ad-5/3-κBF512HRE, a viral variant pseudotyped with a chimeric 5/3 fiber, exerted a strong lytic effect on CAR-negative melanoma cells and was highly effective in vivo on established tumors made of melanoma cells and WI-38 fibroblasts, leading to the complete elimination of 4/5 tumors. These results indicate that this improved stroma-targeted oncolytic adenovirus can override the resistance of melanoma tumors and might become of significant importance for melanoma therapeutics.

Citing Articles

Fibroblast: A Novel Target for Autoimmune and Inflammatory Skin Diseases Therapeutics.

Chen X, Wu Y, Jia S, Zhao M Clin Rev Allergy Immunol. 2024; 66(3):274-293.

PMID: 38940997 DOI: 10.1007/s12016-024-08997-1.

In Vitro and In Vivo Efficacy of a Stroma-Targeted, Tumor Microenvironment Responsive Oncolytic Adenovirus in Different Preclinical Models of Cancer.

Alfano A, Cafferata E, Gangemi M, Nicola Candia A, Malnero C, Bermudez I Int J Mol Sci. 2023; 24(12).

PMID: 37373140 PMC: 10297998. DOI: 10.3390/ijms24129992.

Talimogene Laherparepvec (T-VEC): A Review of the Recent Advances in Cancer Therapy.

Zhang T, Jou T, Hsin J, Wang Z, Huang K, Ye J J Clin Med. 2023; 12(3).

PMID: 36769745 PMC: 9917711. DOI: 10.3390/jcm12031098.

A Single Dose of a Hybrid hAdV5-Based Anti-COVID-19 Vaccine Induces a Long-Lasting Immune Response and Broad Coverage against VOC.

Lopez M, Vinzon S, Cafferata E, Nunez F, Soto A, Sanchez-Lamas M Vaccines (Basel). 2021; 9(10).

PMID: 34696219 PMC: 8537385. DOI: 10.3390/vaccines9101106.

Targeting the extracellular matrix for immunomodulation: applications in drug delivery and cell therapies.

Aghlara-Fotovat S, Nash A, Kim B, Krencik R, Veiseh O Drug Deliv Transl Res. 2021; 11(6):2394-2413.

PMID: 34176099 DOI: 10.1007/s13346-021-01018-0.

References

Garber K . China approves world's first oncolytic virus therapy for cancer treatment. J Natl Cancer Inst. 2006; 98(5):298-300. DOI: 10.1093/jnci/djj111. View

Khoury M, Adriaansen J, Vervoordeldonk M, Gould D, Chernajovsky Y, Bigey P . Inflammation-inducible anti-TNF gene expression mediated by intra-articular injection of serotype 5 adeno-associated virus reduces arthritis. J Gene Med. 2007; 9(7):596-604. DOI: 10.1002/jgm.1053. View

Adriaansen J, Khoury M, de Cortie C, Fallaux F, Bigey P, Scherman D . Reduction of arthritis following intra-articular administration of an adeno-associated virus serotype 5 expressing a disease-inducible TNF-blocking agent. Ann Rheum Dis. 2007; 66(9):1143-50. PMC: 1955149. DOI: 10.1136/ard.2006.064519. View

Guo X, Evans T, Somanath S, Armesilla A, Darling J, Schatzlein A . In vitro evaluation of cancer-specific NF-kappaB-CEA enhancer-promoter system for 5-fluorouracil prodrug gene therapy in colon cancer cell lines. Br J Cancer. 2007; 97(6):745-54. PMC: 2360387. DOI: 10.1038/sj.bjc.6603930. View

Hafner M, Zimmermann K, Pottgiesser J, Krieg T, Nischt R . A purine-rich sequence in the human BM-40 gene promoter region is a prerequisite for maximum transcription. Matrix Biol. 1995; 14(9):733-41. DOI: 10.1016/s0945-053x(05)80016-2. View

Greco O, Marples B, Dachs G, Williams K, Patterson A, Scott S . Novel chimeric gene promoters responsive to hypoxia and ionizing radiation. Gene Ther. 2002; 9(20):1403-11. DOI: 10.1038/sj.gt.3301823. View

Melnikova V, Bar-Eli M . Inflammation and melanoma metastasis. Pigment Cell Melanoma Res. 2009; 22(3):257-67. DOI: 10.1111/j.1755-148X.2009.00570.x. View

Wu X, Chen V, Steele B, Roffers S, Klotz J, Correa C . Cancer incidence in adolescents and young adults in the United States, 1992-1997. J Adolesc Health. 2003; 32(6):405-15. DOI: 10.1016/s1054-139x(03)00057-0. View

Schadendorf D, Algarra S, Bastholt L, Cinat G, Dreno B, Eggermont A . Immunotherapy of distant metastatic disease. Ann Oncol. 2009; 20 Suppl 6:vi41-50. PMC: 2712591. DOI: 10.1093/annonc/mdp253. View

10.

Hendrix M, Seftor E, Hess A, Seftor R . Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat Rev Cancer. 2003; 3(6):411-21. DOI: 10.1038/nrc1092. View

11.

Lee J, Lee Y, Kim J, Kim K, Lee J, Jang H . A novel chimeric promoter that is highly responsive to hypoxia and metals. Gene Ther. 2006; 13(10):857-68. DOI: 10.1038/sj.gt.3302728. View

12.

Senzer N, Kaufman H, Amatruda T, Nemunaitis M, Reid T, Daniels G . Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol. 2009; 27(34):5763-71. DOI: 10.1200/JCO.2009.24.3675. View

13.

Hodi F, ODay S, Mcdermott D, Weber R, Sosman J, Haanen J . Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8):711-23. PMC: 3549297. DOI: 10.1056/NEJMoa1003466. View

14.

Lee S, Kim H, Yu R, Lee K, Gardner T, Jung C . Novel prostate-specific promoter derived from PSA and PSMA enhancers. Mol Ther. 2002; 6(3):415-21. DOI: 10.1006/mthe.2002.0682. View

15.

Rivera A, Davydova J, Schierer S, Wang M, Krasnykh V, Yamamoto M . Combining high selectivity of replication with fiber chimerism for effective adenoviral oncolysis of CAR-negative melanoma cells. Gene Ther. 2004; 11(23):1694-702. DOI: 10.1038/sj.gt.3302346. View

16.

Hogg R, Garcia J, Gerard R . Adenoviral targeting of gene expression to tumors. Cancer Gene Ther. 2010; 17(6):375-86. PMC: 2873120. DOI: 10.1038/cgt.2010.1. View

17.

Lens M, Dawes M . Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br J Dermatol. 2004; 150(2):179-85. DOI: 10.1111/j.1365-2133.2004.05708.x. View

18.

Podhajcer O, Benedetti L, Girotti M, Prada F, Salvatierra E, Llera A . The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host. Cancer Metastasis Rev. 2008; 27(4):691-705. DOI: 10.1007/s10555-008-9146-7. View

19.

Dent P, Yacoub A, Hamed H, Park M, Dash R, Bhutia S . The development of MDA-7/IL-24 as a cancer therapeutic. Pharmacol Ther. 2010; 128(2):375-84. PMC: 2947573. DOI: 10.1016/j.pharmthera.2010.08.001. View

20.

Hsu M, Meier F, Herlyn M . Melanoma development and progression: a conspiracy between tumor and host. Differentiation. 2002; 70(9-10):522-36. DOI: 10.1046/j.1432-0436.2002.700906.x. View